Product Images Metformin Hydrochloride

This text provides information about Metformin hydrochloride tablets, USP, with 850 mg of dosage. The tablets are meant to be dispensed by a pharmacist and are packaged in a controlled room environment with a temperature range of 15°-30°C. The packaging has a specific NDC code and batch information. The manufacturer is Sun Pharmaceutical Industries Ltd with a location in Guiral, India, and it is distributed by Sun Pharmaceutical Industries Inc, located in Cranbury, NJ. The usual dosage and complete product information can be found in the package outset.*

This text appears to be a label of Metformin Hydrochloride Tablets, USP used for treating type 2 diabetes. The label includes information such as the manufacturer, dosage, NDC number, storage conditions, and usual dosage. The medication should be stored at a controlled room temperature of 15°30°C (5"66°F) in a defined container. The usual dosage is not specified, and the package insert should be consulted for complete product information. The Pharmacist information and manufacturing details are also provided.*

This is a pharmacokinetic study of Metformin Hydrochloride Tablets, USP conducted on different subject groups including healthy, non-diabetic adults, adults with type 2 diabetes and renal-impaired adults. The study measured the renal clearance of Metformin, which is expressed in mU/min, after single or multiple oral doses at different doses (500mg, 850mg once, and 850mg thrice daily for 19 doses) for each subject group. The results are presented in Table 1.*

The table compares the effects of taking Metformin Hydrochloride Tablets, USP with a placebo in a 20-week study. It shows the mean changes from baseline levels in fasting plasma glucose, HbAq, and body weight. The results suggest that taking Metformin Hydrochloride Tablets, USP caused significant reductions in fasting plasma glucose and HbAq compared to the placebo. However, there was no significant difference in body weight between the Metformin Hydrochloride Tablets, USP group and the placebo group.*

This is a table that presents the results of a 29-week study comparing the effects of a combination of Metformin Hydrochloride Tablets and Glyburide to Glyburide alone. The table compares the changes in fasting plasma glucose levels, Hemoglobin A1c, and body weight between the two groups. The results show that the combination therapy led to lower fasting plasma glucose levels and greater reductions in body weight compared to Glyburide alone. However, the Hemoglobin A1c levels did not differ significantly between the two groups.*

The given text appears to be a table showing the Summary of Mean Percent Change from Baseline of Major Serum Lipid Variables at the Final Visit (29-week studies). The table contains four different treatments, including Metformin Vs Placebo, Metformin/Glyburide Vs Placebo, Metformin Vs Glimepiride, and Metformin/Glyburide Vs Glimepiride. There are five lipid variables mentioned in the table, including Total Cholesterol, Triglycerides, LDL Cholesterol, HDL Cholesterol, and Total Cholesterol/HDL Cholesterol Ratio. The table also shows the sample size (N) for each treatment group.*

This is a summary of the mean changes from baseline in FPG (fasting plasma glucose) and body weight in a study comparing Metformin Hydrochloride Tablets to placebo. It seems to be related to a pediatric study, but more context is needed.*

Metformin Hydrochloride is a medication that helps treat type 2 diabetes. It comes in tablet form, with each pill containing 500 mg of Metformin Hydrochloride USP. The pharmacist should dispense this medication in a tight, light-resistant container and store it at a controlled temperature between 15°-30°C. The manufacturer is Sun Pharmaceutical Industries, located in Gujarat, India, and it is distributed by Sun Pharmaceutical Industries, Inc., based in Cranbury, NJ. The recommended dosage should be specified in the package outsert, and the product is available upon prescription only. The text also includes a unique identification code, lot number, and issuance date.*